TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03108638

Intervention type: BEHAVIORAL
Intervention: R3 Supervisor Implementation Strategy
Description: Supervisors will be trained to provide supervision to their caseworkers using R3 principles and strategies. Monthly monitoring and remote coaching will be provided.

Intervention type: BEHAVIORAL
Intervention: R3 Supervisor Implementation Strategy
Description: Supervisors will be trained to provide supervision to their caseworkers using R3 principles and strategies. Monthly monitoring and remote coaching will be provided.

Intervention type: BEHAVIORAL
Intervention: R3 Supervisor Implementation Strategy
Description: Supervisors will be trained to provide supervision to their caseworkers using R3 principles and strategies. Monthly monitoring and remote coaching will be provided.

Intervention type: BEHAVIORAL
Intervention: R3 Supervisor Implementation Strategy
Description: Supervisors will be trained to provide supervision to their caseworkers using R3 principles and strategies. Monthly monitoring and remote coaching will be provided.
Study: NCT01427738

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gentian Violet
Description: Participants were administered topical Gentian violet solution, orally, twice daily for 14 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nystatin oral suspension
Description: Participants were administered Nystatin oral suspension 4 times a day for 14 days.
Study: NCT05127018

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: injection of Botulinum type A
Description: The participates were allocated to two different application methods: Simplified Method for the first injection and Individualized Method 8 months later. All the patients underwent twice injection with each methods with no change of the BTX-A(Botox, Allergan, Irvine, CA) and other injection details: Lyophilized 100 U of Botox was reconstituted in 2.5 mL of 0.9% sodium chloride solution. The injections were made with a 27-gauge insulin syringe. The treatment was an outpatient procedure and all injections were performed by one of the authors (X.G.). No anesthesia was given during the procedure.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: injection of Botulinum type A
Description: The participates were allocated to two different application methods: Simplified Method for the first injection and Individualized Method 8 months later. All the patients underwent twice injection with each methods with no change of the BTX-A(Botox, Allergan, Irvine, CA) and other injection details: Lyophilized 100 U of Botox was reconstituted in 2.5 mL of 0.9% sodium chloride solution. The injections were made with a 27-gauge insulin syringe. The treatment was an outpatient procedure and all injections were performed by one of the authors (X.G.). No anesthesia was given during the procedure.
Study: NCT02761863

Intervention type: OTHER
Intervention: CD 74, VEGF detection
Description: All MPM samples will be subjected to immunohistochemistry with CD74 and VEGF antibodies.~The VEGF will be scored using a 0-3 scoring system to represent the percentage of cytoplasmic positively stained cells in the tumor portion, as follows: 0-10%, 11-30%, 31-60% and 61-100% positive staining correspond to score 0, 1, 2 and 3 respectively. Both CD74 and VEGF immunohistochemical markers will be furtherly categorized in the statistical analyses as none (0)/low (1) vs medium (2)/high expression(3).~The CD74 expression will be recorded in the tumor and the stroma semiquantitatively using the histoscore method using four representative fields with the final score resulting from the percentage of tumor cells staining positively multiplied by the staining intensity grade.
Study: NCT01076998

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lubricant eye drop FID 115958D
Description: 1 drop in each eye, one time

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Refresh PM Ointment
Description: 1 drop in each eye, one time
Study: NCT05804682

Intervention type: PROCEDURE
Intervention: Fascial Neck Dissection
Description: Central and lateral neck dissection with the fascial technique

Intervention type: PROCEDURE
Intervention: Standard Neck Dissection
Description: Central and lateral neck dissection with the standard technique
Study: NCT00841230

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deanxit
Description: Deanxit 1x/day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lactose placebo
Description: Lactose used as placebo
Study: NCT02719756

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin tablets 1000 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Metformin tablets 1000 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: Dapagliflozin 10 mg tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin up-titration
Study: NCT02302703

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: low FODMAP diet vs Gluten free diet

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: low FODMAP diet vs Gluten free diet
Study: NCT00523952

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tacrolimus ointment
Description: tacrolimus, single arm, 0.1 ointment
Study: NCT00223210

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Quetiapine
Description: Active Quetiapine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PLacebo
Description: Placebo
Study: NCT00511498

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sildenafil
Description: 50 mg daily at bedtime

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sildenafil
Description: 50 mg daily at bedtime
Study: NCT01837589

Intervention type: OTHER
Group type: OTHER
Intervention: QCT

Intervention type: OTHER
Group type: OTHER
Intervention: DXA
Study: NCT03156205

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: interactive music therapy
Description: For the interactive music therapy intervention group, each patient received individual interactive music therapy sessions administered by professional music therapists during daytime; the patient participated in listening to music predetermined based on his/her preference during night time.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: passive music listening
Description: For the passive music listening group, each patient participated in music listening during night time without involving in interactive music therapy sessions during daytime.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: passive earphone-use
Description: For the passive earphone use group (control group), each participant used headphone and eye mask without music listening at night time.
Study: NCT03478410

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Epicardial fat biopsy
Description: A 1 cm (\~0.5 g) of epicardial pat biopsy from the area of the pulmonary artery

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Epicardial fat biopsy
Description: A 1 cm (\~0.5 g) of epicardial pat biopsy from the area of the pulmonary artery
Study: NCT03779477

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Coping with Stress Course
Description: The Coping with Stress Program is a group program, which is developed by Clarke and Lewinson (1995) for the prevention of depression in high-risk adolescents. It is based on cognitive-behavioral therapy principles and contains psychoeducation and cognitive-behavioral therapy interventions. There are handbooks available for the group leader of the program and the participating adolescents. In the handbook developed for the group leader, there is detailed information about the objective of each session and the implemented interventions. The adolescents will find lists organized for the fulfillment of the tasks in the handbook prepared for them. The handbooks of the program were translated in Turkish and experts were consulted for their validity.
Study: NCT00136682

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: patient-controlled epidural analgesia (PCEA)
Description: During the consent process you will be given a patient data sheet to assess your baseline pain and itchiness. While in the hospital you will be given a patient data sheet to fill out information regarding pain, nausea, when you passed gas, and when you ate food. This will be done once a day by a research assistant or by the research investigators.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: patient-controlled intravenous analgesia (PCA)
Description: During the consent process you will be given a patient data sheet to assess your baseline pain and itchiness. While in the hospital you will be given a patient data sheet to fill out information regarding pain, nausea, when you passed gas, and when you ate food. This will be done once a day by a research assistant or by the research investigators.
Study: NCT04322812

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active PBMT
Description: The Active PBMT will be applied using MR5™ ACTIV PRO LaserShower Laser Therapy System, manufactured by Multi Radiance Medical (Solon, OH, USA) will be used. The ACTIV PRO emits 30mW of 905nm, 300mW of 850nm, 200mW of 660nm and 0mW of 455nm light via an electric diode energy source. PBMT will be applied using the direct contact method with light pressure on the skin. The PBMT application time will be 120 seconds per region and the total time will vary according to the number of regions to be treated. Only the painful regions on that day will be treated (according widespread pain index \[WPI\] ), which can comprise a minimum of 3 and a maximum of 18 regions in total. The dose used for applications during the treatment will be 60 Joules (J) per region. The total dose might vary between patients and each session.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo PBMT
Description: The placebo PBMT will be applied using MR5™ ACTIV PRO LaserShower Laser Therapy System, manufactured by Multi Radiance Medical (Solon, OH, USA). The ACTIV PRO emits 905nm, and 850nm via an electric diode energy source with outputs to 0%. The 660nm light via an electric diode energy source with outputs to \>1% to appear like the active comparator. PBMT will be applied using the direct contact method with light pressure on the skin. The placebo PBMT application time will be 115 seconds per region and the total time will vary according to the number of regions to be treated. Only the painful regions on that day will be treated (according WPI), which can comprise a minimum of 3 and a maximum of 18 regions in total. The dose used for applications during the treatment will be 0 Joules (J) per region. The sounds and signals emitted from the device as well as the information displayed on the screen will be identical, regardless of the type of treatment (active or placebo).
Study: NCT01638845

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: continuous perineural catheter
Description: continuous perineural catheter
Study: NCT01454232

Intervention type: OTHER
Group type: OTHER
Intervention: stools sampling
Description: stools sampling at baseline, 1, 3 and 12 months

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: stools sampling
Description: stools sampling at baseline, 1, 3 and 12 months

Intervention type: OTHER
Group type: OTHER
Intervention: adipose tissue biopsy
Description: surgical adipose tissue biopsy during surgery, 1, 3 and 12 months

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: adipose tissue biopsy
Description: surgical adipose tissue biopsy during surgery, 1, 3 and 12 months
Study: NCT03537378

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hybrid APC
Description: • HybridAPC is integrated with traditional APC and water-jet technique, which has been successfully applied for endoscopic treatment of mucosal lesions in GI, such as Barrett esophageal and lesions in colon. Submucosal injection of water jet can elevate superficial lesion, and then APC can be more effective in ablation of superficial tumor with a protection for muscular layer. The application of HybridAPC in respiratory intervention could theoretically protect cartilage, adventitia, reduce damage and formation of scare, and increase ablation energy to reach radical treatment. • High-frequency EBUS, could display the boundary between cartilage endomembrane and cartilage, in order to determine the depth of tumor.
Study: NCT00569010

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Group 1 and 3 at Level 0 = 37.5 mg/m\^2 IV Over 20-30 minutes Daily for 7 Days Group 2 and 4 at Level 1 = 75.0 mg/m\^2 IV Over 20-30 minutes Daily for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Group 1 and 3 at Level 0 = 37.5 mg/m\^2 IV Over 20-30 minutes Daily for 7 Days Group 2 and 4 at Level 1 = 75.0 mg/m\^2 IV Over 20-30 minutes Daily for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Group 1 and 3 at Level 0 = 37.5 mg/m\^2 IV Over 20-30 minutes Daily for 7 Days Group 2 and 4 at Level 1 = 75.0 mg/m\^2 IV Over 20-30 minutes Daily for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Group 1 and 3 at Level 0 = 37.5 mg/m\^2 IV Over 20-30 minutes Daily for 7 Days Group 2 and 4 at Level 1 = 75.0 mg/m\^2 IV Over 20-30 minutes Daily for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ara-C
Description: Group 1 and 2 at Low-Dose = 100 mg/m\^2 Daily continuous intravenous infusion (CIV) for 7 days~Arms 3 and 4 at High-dose = 1 g/m\^2 Daily CIV for 4 days (age\<65 years) or 3 days (age\>=65 years)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ara-C
Description: Group 1 and 2 at Low-Dose = 100 mg/m\^2 Daily continuous intravenous infusion (CIV) for 7 days~Arms 3 and 4 at High-dose = 1 g/m\^2 Daily CIV for 4 days (age\<65 years) or 3 days (age\>=65 years)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ara-C
Description: Group 1 and 2 at Low-Dose = 100 mg/m\^2 Daily continuous intravenous infusion (CIV) for 7 days~Arms 3 and 4 at High-dose = 1 g/m\^2 Daily CIV for 4 days (age\<65 years) or 3 days (age\>=65 years)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ara-C
Description: Group 1 and 2 at Low-Dose = 100 mg/m\^2 Daily continuous intravenous infusion (CIV) for 7 days~Arms 3 and 4 at High-dose = 1 g/m\^2 Daily CIV for 4 days (age\<65 years) or 3 days (age\>=65 years)
Study: NCT04505618

Intervention type: DEVICE
Group type: OTHER
Intervention: Spectral-Domain (SD) OCT Angiography
Description: Non-invasive, minimal risk, ocular imaging study

Intervention type: DEVICE
Group type: OTHER
Intervention: Spectral-Domain (SD) OCT Angiography
Description: Non-invasive, minimal risk, ocular imaging study
Study: NCT01461005

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dynamic Stabilization System (DSS)
Description: Dynamic Stabilization System
Study: NCT06266598

Intervention type: DRUG
Group type: OTHER
Intervention: Metformin
Description: Only obese children with insulin resistance were treated with metformin.
Study: NCT04505618

Intervention type: DEVICE
Group type: OTHER
Intervention: Fundus Imaging
Description: Non-invasive, minimal risk, ocular imaging study

Intervention type: DEVICE
Group type: OTHER
Intervention: Fundus Imaging
Description: Non-invasive, minimal risk, ocular imaging study

Intervention type: DEVICE
Group type: OTHER
Intervention: Fundus Imaging
Description: Non-invasive, minimal risk, ocular imaging study

Intervention type: DEVICE
Group type: OTHER
Intervention: Fundus Imaging
Description: Non-invasive, minimal risk, ocular imaging study

Intervention type: DEVICE
Group type: OTHER
Intervention: Axial Length Measurement Device
Description: Non-invasive, minimal risk, ocular imaging study
Study: NCT00983112

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Human Fibrinogen and human thrombin (Evicel)
Description: Product to be applied intraoperatively. No further administration will take place after this.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium Chlorure (Physiological saline)
Description: Sterile concentration, local use.
Study: NCT05006222

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enzyme Replacement Agent
Description: Enzyme replacement therapy is one such treatment and used for the management of some subtypes of MPS disease. Enzyme replacement therapy (ERT) is based on the concept of replacing the missing enzyme in the circulation to prevent the build-up of glycosaminoglycan (GAG) in the tissues
Study: NCT01999777

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: USL261
Study: NCT04505618

Intervention type: DEVICE
Group type: OTHER
Intervention: Axial Length Measurement Device
Description: Non-invasive, minimal risk, ocular imaging study

Intervention type: DEVICE
Group type: OTHER
Intervention: Axial Length Measurement Device
Description: Non-invasive, minimal risk, ocular imaging study

Intervention type: DEVICE
Group type: OTHER
Intervention: Axial Length Measurement Device
Description: Non-invasive, minimal risk, ocular imaging study
Study: NCT00676416

Intervention type: DRUG
Intervention: 2,6-Diisopropylphenol
Description: Propofol general anesthesia was performed in patients with asthma (1) and without asthma (2)

Intervention type: DRUG
Intervention: 2,6-Diisopropylphenol
Description: Propofol general anesthesia was performed in patients with asthma (1) and without asthma (2)
Study: NCT04350814

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-Compassion Step by Step
Description: This is a 6-lesson self-guided audio program by Dr. Kristen Neff (2013)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-Reflection Active Control
Description: Participants randomized to this active control condition will be asked to complete study measures at the same intervals as those assigned to the intervention condition. In addition to completing study questionnaires, participants in this arm will also be invited to reflect on their weekly reported symptoms, whether they experienced changed, what they believe these changes are attributed to, etc.
Study: NCT04466605

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tele-yoga therapy
Description: Each session included combinations of different yoga exercises, postures, yoga breathing, yoga relaxation techniques, yoga counselling and meditative practices based on individualisation.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Primary care
Description: Patients will follow standard care provided by primary care physicians including analgesics and self care management.
Study: NCT01243294

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SS
Description: New ostomy appliance (SS) is tested in 10 ± 2 days and the degree of leakage under the baseplate is measured and compared to SenSura.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SS
Description: New ostomy appliance (SS) is tested in 10 ± 2 days and the degree of leakage under the baseplate is measured and compared to SenSura.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SenSura
Description: New ostomy appliance (SS) is tested in 10 ± 2 days and the degree of leakage under the baseplate is measured and compared to SenSura.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SenSura
Description: New ostomy appliance (SS) is tested in 10 ± 2 days and the degree of leakage under the baseplate is measured and compared to SenSura.
Study: NCT05173285

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Baseline Assessment
Description: At baseline (i.e. Pre-intervention) participants will complete several questionnaires online via Qualtrics.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Baseline Assessment
Description: At baseline (i.e. Pre-intervention) participants will complete several questionnaires online via Qualtrics.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Online ACT Intervention
Description: Participants will complete the 4-week online intervention via Qualtrics

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Post-Intervention Assessment (i.e. between 4-6 weeks after baseline assessment)
Description: Participants will complete several questionnaires online via Qualtrics.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Post-Intervention Assessment (i.e. between 4-6 weeks after baseline assessment)
Description: Participants will complete several questionnaires online via Qualtrics.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Follow-up Assessment (i.e. between 8-12 weeks after baseline assessment)
Description: Participants will complete several questionnaires online via Qualtrics.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Follow-up Assessment (i.e. between 8-12 weeks after baseline assessment)
Description: Participants will complete several questionnaires online via Qualtrics.
Study: NCT01389258

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OsseoSpeed™ TX
Description: OsseoSpeed™ TX narrow implants (diameter 3 mm) of lengths 11-15 mm
Study: NCT01547052

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DBT for children
Description: intervention consists of weekly individual 45 min. sessions, twice per week 60 min. group sessions, and every other week 90 min. sessions with parents
Study: NCT01999777

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03666806

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza vaccine
Description: The randomized FLUVACS trial demonstrated the benefits of influenza vaccination in the prevention of cardiovascular death. In the VIPS study the risk for acute ischaemic stroke (AIS) in children increased by 6-fold compared to the baseline population. It was postulated that infections and in particular upper respiratory tract infections acts as a stroke trigger in a child who is otherwise predisposed to stroke and why it would occur at a particular point in that child's life. It should be noted that major infections such as meningitis have been causes of stroke while this study has shown that minir infections can also act as a trigger for stroke in adults
Study: NCT01547052

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Supportive-Educational therapy
Description: weekly individual 45 min sessions, twice per week 60 min. group sessions and every other week parent sessions.
Study: NCT01615978

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liraglutide
Description: 5 mcg/kg daily for 14 days. Injected subcutaneously once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liraglutide
Description: Initial dose of 5 mcg/kg for 7 days followed by 10 mcg/kg for 7 days. Injected subcutaneously once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Liraglutide placebo administered to subjects randomised at each dose level in the ratio of 3:1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Liraglutide placebo administered to subjects randomised at each dose level in the ratio of 3:1